NO20053595L - Escitalopramdibromid samt fremgangsmate ved fremstilling derav. - Google Patents

Escitalopramdibromid samt fremgangsmate ved fremstilling derav.

Info

Publication number
NO20053595L
NO20053595L NO20053595A NO20053595A NO20053595L NO 20053595 L NO20053595 L NO 20053595L NO 20053595 A NO20053595 A NO 20053595A NO 20053595 A NO20053595 A NO 20053595A NO 20053595 L NO20053595 L NO 20053595L
Authority
NO
Norway
Prior art keywords
escitalopram
dibromide
citalopram
hydrobromide
processes
Prior art date
Application number
NO20053595A
Other languages
English (en)
Norwegian (no)
Inventor
Hans Petersen
Peter Ellegaard
Robert Dancer
Lawrence Martel
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053595(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20053595L publication Critical patent/NO20053595L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20053595A 2002-12-23 2005-07-25 Escitalopramdibromid samt fremgangsmate ved fremstilling derav. NO20053595L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
PCT/DK2003/000902 WO2004056791A1 (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Publications (1)

Publication Number Publication Date
NO20053595L true NO20053595L (no) 2005-09-05

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053595A NO20053595L (no) 2002-12-23 2005-07-25 Escitalopramdibromid samt fremgangsmate ved fremstilling derav.

Country Status (32)

Country Link
US (1) US20040167209A1 (enExample)
EP (1) EP1578738B1 (enExample)
JP (2) JP4658613B2 (enExample)
KR (1) KR20050086933A (enExample)
CN (1) CN100349885C (enExample)
AR (1) AR042652A1 (enExample)
AT (1) ATE388947T1 (enExample)
AU (1) AU2003287919B2 (enExample)
BR (1) BR0317623A (enExample)
CA (1) CA2511142A1 (enExample)
CY (1) CY1107451T1 (enExample)
DE (1) DE60319739T2 (enExample)
DK (1) DK1578738T3 (enExample)
EA (1) EA013116B1 (enExample)
EG (1) EG24729A (enExample)
ES (1) ES2298595T3 (enExample)
IL (1) IL169125A0 (enExample)
IS (1) IS2654B (enExample)
ME (1) MEP5808A (enExample)
MX (1) MXPA05005772A (enExample)
MY (1) MY135468A (enExample)
NO (1) NO20053595L (enExample)
NZ (1) NZ540281A (enExample)
PE (1) PE20040924A1 (enExample)
PL (1) PL378275A1 (enExample)
PT (1) PT1578738E (enExample)
RS (1) RS51092B (enExample)
TW (1) TW200501943A (enExample)
UA (1) UA80170C2 (enExample)
UY (1) UY28148A1 (enExample)
WO (1) WO2004056791A1 (enExample)
ZA (1) ZA200504109B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317623A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
JP5501615B2 (ja) * 2006-07-11 2014-05-28 田辺三菱製薬株式会社 モルホリン化合物の塩
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
RU2020111694A (ru) * 2017-10-09 2021-11-12 Тева Фармасьютикал Индастриз Лтд. Новые соли и твердые формы эсциталопрама
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ATE230738T1 (de) * 1998-10-20 2003-01-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
PT1298124E (pt) * 1999-10-25 2007-05-31 Lundbeck & Co As H Método para a preparação de citalopram
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
IES20010693A2 (en) * 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
WO2002046340A1 (de) * 2000-12-04 2002-06-13 Dr. Frische Gmbh Verfahren zur herstellung von fettsaüreestern
MXPA03008777A (es) * 2001-05-01 2004-02-12 Lundbeck & Co As H El uso de escitalopram enantiomericamente puro.
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
BR0317623A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Also Published As

Publication number Publication date
AR042652A1 (es) 2005-06-29
ATE388947T1 (de) 2008-03-15
DE60319739T2 (de) 2008-07-17
JP4658613B2 (ja) 2011-03-23
EA013116B1 (ru) 2010-02-26
WO2004056791A1 (en) 2004-07-08
RS20050487A (sr) 2007-06-04
IS2654B (is) 2010-08-15
AU2003287919A1 (en) 2004-07-14
ZA200504109B (en) 2006-08-30
JP2011037893A (ja) 2011-02-24
KR20050086933A (ko) 2005-08-30
CA2511142A1 (en) 2004-07-08
EP1578738B1 (en) 2008-03-12
PT1578738E (pt) 2008-04-11
DK1578738T3 (da) 2008-06-30
PE20040924A1 (es) 2004-12-11
MY135468A (en) 2008-04-30
AU2003287919B2 (en) 2009-11-12
PL378275A1 (pl) 2006-03-20
EA200501046A1 (ru) 2005-12-29
DE60319739D1 (de) 2008-04-24
CN1726202A (zh) 2006-01-25
ES2298595T3 (es) 2008-05-16
CY1107451T1 (el) 2012-12-19
CN100349885C (zh) 2007-11-21
MXPA05005772A (es) 2005-08-16
TW200501943A (en) 2005-01-16
RS51092B (sr) 2010-10-31
NZ540281A (en) 2008-07-31
MEP5808A (xx) 2010-02-10
JP2006514952A (ja) 2006-05-18
EG24729A (en) 2010-06-21
UY28148A1 (es) 2004-09-30
EP1578738A1 (en) 2005-09-28
IS7848A (is) 2005-05-17
BR0317623A (pt) 2005-11-29
US20040167209A1 (en) 2004-08-26
HK1087708A1 (en) 2006-10-20
UA80170C2 (en) 2007-08-27
IL169125A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
SG130189A1 (en) Substituted indole-o-glucosides
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
UA87991C2 (en) Substituted indole-o-glucosides
CY1107451T1 (el) Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου
WO2005011592A3 (en) Substituted indazole-o-glucosides
DE50015623D1 (de) Kovalent verbrückte insulindimere
SE0100901D0 (sv) New composition
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
NO20070391L (no) Jernsulfatbasert fosfatadsorbent
DE50204688D1 (de) N-alkylaziridinoprepolymere als dentalmasse
NO20050091L (no) Fremgangsmater for fremstilling av fibrinogen
DK1465641T3 (da) Lægemidler indeholdende deuterium til behandling af sukkersyge
HU229456B1 (en) Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
NO20041200L (no) Fremgangsmate for fremstilling av citalopram.
GB0216002D0 (en) Process and composition
NO20031648L (no) Farmasöytiske lösninger av modafinilforbindelser
MXPA03007635A (es) P-tienilbencilamidas que sirven como agonistas de receptores para angiotensina-(1-7), metodo para su produccion, su uso y preparaciones farmaceuticas que las contienen.
NO20026128L (no) Gelformet drivstoff, fremgangsmåte for dets fremstilling og dets anvendelse
NO331195B1 (no) Fremgangsmate for fremstilling av halogen-substituerte monosulfider og deres hydroksymonosulfid-evkivalenter som mellomprodukter.
NO20033318L (no) 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav
JP2004500380A5 (enExample)
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application